6533b7d7fe1ef96bd1268f05

RESEARCH PRODUCT

Marine Actinomycetes-Derived Secondary Metabolites Overcome TRAIL-Resistance via the Intrinsic Pathway through Downregulation of Survivin and XIAP

Mohammed I. Y. ElmallahMohammed I. Y. ElmallahMohammed I. Y. ElmallahOlivier MicheauOlivier MicheauAndrei ConstantinescuAndrei ConstantinescuSelene Elifio-espositoSheron Campos CogoSheron Campos CogoSheron Campos CogoMohammed Saleh Hamed Abdelfattah

subject

0301 basic medicineAquatic OrganismsProgrammed cell deathCell SurvivalSurvivinDown-RegulationSecondary MetabolismX-Linked Inhibitor of Apoptosis ProteinTRAILJurkat cellsArticleTNF-Related Apoptosis-Inducing LigandJurkat Cells03 medical and health sciences0302 clinical medicinemarine actinomycetesDownregulation and upregulationDrug DiscoveryOxazinesSurvivinHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyFADDBenzopyreneslcsh:QH301-705.5ComputingMilieux_MISCELLANEOUSCaspase 8therapybiologyChemistryProdigiosinQuinonesapoptosisGeneral MedicineHCT116 Cells3. Good healthXIAPActinobacteria030104 developmental biologylcsh:Biology (General)Drug Resistance NeoplasmApoptosis030220 oncology & carcinogenesisCancer cellbiology.proteinCancer researchGene Deletion

description

Resistance of cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis represents the major hurdle to the clinical use of TRAIL or its derivatives. The discovery and development of lead compounds able to sensitize tumor cells to TRAIL-induced cell death is thus likely to overcome this limitation. We recently reported that marine actinomycetes&rsquo

yearjournalcountryeditionlanguage
2020-07-01Cells
https://doi.org/10.3390/cells9081760